Ozempic NAION Warning: FDA Adds Rare Eye Risk to Every GLP-1 Drug Label
The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn of NAION, a rare cause of sudden vision loss. Here is what the data show.
The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn of NAION, a rare cause of sudden vision loss. Here is what the data show.
Innogen has licensed its China-approved GLP-1 efsubaglutide alfa to Arcera for Africa, Eastern Europe, Latin America and the Middle East in a deal worth over $1 billion.
A Science review weighs whether Ozempic, Wegovy and Mounjaro protect the brain. Observational data look promising, but Alzheimer trials were negative. What we know.
Advagen Pharma is recalling one lot of metoprolol tartrate 50 mg tablets, about 3.68 million pills, after foreign tablets or capsules were found. What patients should do.
India proposes treating antimicrobials as new drugs under NDCT Rules via draft G.S.R. 983(E), requiring CLA permission before state manufacturing licences. Comments open 30 days.
Aragen Life Sciences plans Rs 150 crore of expansion alongside an IPO with a Rs 800 crore fresh issue. Financials, capacity targets and what investors still do not know.
India has proposed a separate wholesale licence for bulk drugs and APIs, with new Forms 19-BC and 20-BC, NDPS coverage and a 30-day comment window. What changes for traders.
India has proposed writing Good Storage and Distribution Practices into the Drugs Rules, 1945 and easing revised Schedule M for medicinal gases, capsule shells and disinfectants.
87% of FDA drug inspections in India were unannounced in fiscal 2026, up from 47%. What the surprise-audit shift means for Indian generic makers.
Maharashtra FDA seized about Rs 1.38 crore of nutraceuticals with NMN and magnesium acetyl taurate. What the crackdown means for NMN supplements in India.